Skip to main content
×
Home
    • Aa
    • Aa

Effective case/infection ratio of poliomyelitis in vaccinated populations

  • G. BENCSKÓ (a1) (a2) and T. FERENCI (a3)
Summary
SUMMARY

Recent polio outbreaks in Syria and Ukraine, and isolation of poliovirus from asymptomatic carriers in Israel have raised concerns that polio might endanger Europe. We devised a model to calculate the time needed to detect the first case should the disease be imported into Europe, taking the effect of vaccine coverage – both from inactivated and oral polio vaccines, also considering their differences – on the length of silent transmission into account by deriving an ‘effective’ case/infection ratio that is applicable for vaccinated populations. Using vaccine coverage data and the newly developed model, the relationship between this ratio and vaccine coverage is derived theoretically and is also numerically determined for European countries. This shows that unnoticed transmission is longer for countries with higher vaccine coverage and a higher proportion of IPV-vaccinated individuals among those vaccinated. Assuming borderline transmission (R = 1·1), the expected time to detect the first case is between 326 days and 512 days in different countries, with the number of infected individuals between 235 and 1439. Imperfect surveillance further increases these numbers, especially the number of infected until detection. While longer silent transmission does not increase the number of clinical diseases, it can make the application of traditional outbreak response methods more complicated, among others.

Copyright
Corresponding author
* Author for correspondence: Dr T. Ferenci, John von Neumann Faculty of Informatics, Physiological Controls Group, Óbuda University, H-1034, Bécsi út 96/b, Budapest, Hungary. (Email: ferenci.tamas@nik.uni-obuda.hu)
References
Hide All
1. AtkinsonW, WolfeS, HamborskyJ (eds). Epidemiology and Prevention of Vaccine-preventable Diseases. Washington DC: Centers for Disease Control and Prevention, 2012.
2. WilsonW, SandeM (eds). Current Diagnosis and Treatment in Infectious Diseases. New York: McGraw-Hill, 2001.
3. PlotkinSA, OrensteinW, OffitPA. Vaccines. Philadelphia: Elsevier, 2012.
4. TebbensRJD, et al. Expert review on poliovirus immunity and transmission. Risk Analysis 2013; 33: 544605.
5. AylwardB, et al. When is a disease eradicable? 100 years of lessons learned. American Journal of Public Health 2000; 90: 15151520.
6. HaganJE, et al. Progress toward polio eradication – worldwide, 2014–2015. Morbidity and Mortality Weekly Report 2015; 64: 527531.
7. BahlS, et al. Polio-free certification and lessons learned–South-East Asia Region, March 2014. Morbidity and Mortality Weekly Report 2014; 63: 941946.
8. WHO. Polio eradication and endgame strategic plan 2013–2018. World Health Organization, 2013.
9. European Centre for Disease Prevention and Control. Wild-type poliovirus 1 transmission in Israel – what is the risk to the EU/EEA? (http://www.ecdc.europa.eu/en/publications/Publications/polio-risk-assessment-transmission-in-Israel.pdf). Accessed 30 January 2014).
10. European Centre for Disease Prevention and Control. Outbreak of circulating vaccine-derived poliovirus type 1 (cVDPV1) in Ukraine (http://ecdc.europa.eu/en/publications/Publications/Poliomyelitis-Ukraine-rapid-risk-assessment-September-2015.pdf). Accessed 23 September 2015).
11. EichnerM, BrockmannSO. Polio emergence in Syria and Israel endangers Europe. Lancet 2013; 382: 1777.
12. EichnerM, DietzK. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? American Journal of Epidemiology 1996; 143: 816822.
13. OrensteinWA, et al. Field evaluation of vaccine efficacy. Bulletin of the World Health Organization 1985; 63: 10551068.
14. NathansonN, KewOM. From emergence to eradication: the epidemiology of poliomyelitis deconstructed. American Journal of Epidemiology 2010; 172: 12131229.
15. Advisory Committee on Immunization Practices (ACIP). Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports 1997; 46: 125.
16. WHO CISID database. Polio 3. % of infants vaccinated against (http://data.euro.who.int/cisid/). Accessed 30 January 2014).
17. BurtonA, et al. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bulletin of the World Health Organization 2009; 87: 535541.
18. Eurostat database. Population on 1 January by age and sex. Demo_pjan (http://appsso.eurostat.ec.europa.eu/nui/show.do?dataset=demo_pjan&lang=en). Accessed 30 January 2014).
19. HirdTR, GrasslyNC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathogens 2012; 8: e1002599.
20. OkayasuH, et al. Mucosal immunity and poliovirus vaccines: impact on wild poliovirus infection and transmission. Vaccine 2011; 29: 82058214.
21. SaltelliA, et al. Global Sensitivity Analysis: the Primer. Chichester: Wiley, 2008.
22. SilvermanBW. Density Estimation for Statistics and Data Analysis. Boca Raton, FL: CRC Press, 1986.
23. Wolfram Research, Inc. Mathematica, version 9.0. Champaign, IL, 2012.
24. GaryHE, SandersR, PallanschMA. A theoretical framework for evaluating the sensitivity of surveillance for detecting wild poliovirus: II. Factors affecting detection sensitivity in a population with circulating wild poliovirus. Journal of Infectious Diseases 1997; 175: S141145.
25. WatkinsRE, et al. An evaluation of the sensitivity of acute flaccid paralysis surveillance for poliovirus infection in Australia. BMC Infectious Diseases 2009; 9: 162.
26. ModeCJ, CandaceK. Stochastic Processes in Epidemiology: HIV/AIDS, Other Infectious Diseases, and Computers. Singapore: World Scientific Publishing, 2010.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
UNKNOWN
Supplementary Materials

Bencskó and Ferenci supplementary material
Table S1

 Unknown (80 KB)
80 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 7
Total number of PDF views: 37 *
Loading metrics...

Abstract views

Total abstract views: 405 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th October 2017. This data will be updated every 24 hours.